REFRACTORY
Clinical trials for REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY trials appear
Sign up with your email to follow new studies for REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New laser hope for diabetic eye disease
Disease control Recruiting nowThis study tests a special laser (micropulse) to treat diabetic macular edema, a swelling in the back of the eye that can blur vision. Researchers will compare how well it works in people getting treatment for the first time versus those who haven't improved with other treatments…
Matched conditions: REFRACTORY
Sponsor: The General Authority for Teaching Hospitals and Institutes • Aim: Disease control
Last updated May 26, 2026 05:03 UTC
-
Engineered immune cells take on lupus in first human trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called MC-1-50 for adults with severe lupus that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty immune cells driving the disease. The main goals are to ch…
Matched conditions: REFRACTORY
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated May 26, 2026 05:03 UTC
-
New CAR-T therapy aims to tame hard-to-treat hodgkin lymphoma
Disease control Recruiting nowThis study tests a new treatment for people with Hodgkin lymphoma whose cancer has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The goal is to find a safe dos…
Matched conditions: REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
AI and lab tests aim to find best cancer treatment in two weeks
Knowledge-focused Recruiting nowThis study is testing a new approach called xDRIVE that combines lab tests on tumor samples with artificial intelligence to suggest personalized cancer treatments. It involves 210 Florida patients with cancers that have come back or not responded to standard therapy, including ch…
Matched conditions: REFRACTORY
Phase: NA • Sponsor: First Ascent Biomedical Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 05:00 UTC